title: A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement.
abstract: Molecular testing for anomalies, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) rearrangement, is part of the current standard of care for non-small cell lung cancer, particularly adenocarcinoma. ALK rearrangement occurs most frequently in adenocarcinoma cells and rarely in non-adenocarcinoma cells. We herein report a rare case of pleomorphic lung carcinoma with ALK rearrangement in both its adenocarcinoma and spindle cell components. This case suggests the possibility of ALK rearrangement in pleomorphic carcinoma.
authors.affiliation: Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Shiroyama
authors.forename: Ayako
authors.initials: A
authors.lastname: Tanaka
authors.forename: Motohiro
authors.initials: M
authors.lastname: Tamiya
authors.forename: Masanari
authors.initials: M
authors.lastname: Hamaguchi
authors.forename: Akio
authors.initials: A
authors.lastname: Osa
authors.forename: Sawa
authors.initials: S
authors.lastname: Takeoka
authors.forename: Eriko
authors.initials: E
authors.lastname: Tani
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Azuma
authors.forename: Naoko
authors.initials: N
authors.lastname: Morishita
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Norio
authors.initials: N
authors.lastname: Okamoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Kimura
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kadota
authors.forename: Kunimitsu
authors.initials: K
authors.lastname: Kawahara
authors.forename: Tomonori
authors.initials: T
authors.lastname: Hirashima
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D002945:Cisplatin; D000077235:Vinorelbine